# Emergent BioSolutions

supplies anthrax vaccine and smallpox medical countermeasures under direct government delivery contracts, including a contract with the US Department of War and international government partners.


Source: https://en.bioecon.ru/companies/emergent-biosolutions/
Updated: 2026-08-15

- Country: United States
- Ticker: NYSE:EBS

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $743 million for 2025 | https://www.emergentbiosolutions.com/wp-content/uploads/2026/08/EBSI-Corporate-Fact-Sheet-8-11-26.pdf |
| Headcount | 850 employees | https://www.emergentbiosolutions.com/wp-content/uploads/2026/08/EBSI-Corporate-Fact-Sheet-8-11-26.pdf |
| Funding | $52.7 million contract modification (June 2026) for ACAM2000 | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-contract-modification-valued, https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award, https://investors.emergentbiosolutions.com/node/23881/pdf, https://synapse.patsnap.com/article/emergent-biosolutions-secures-250m2B-in-contracts-for-key-medical-supplies-to-us-government, https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/pressrelease_010825.htm, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/exhibit108mod2-biothraxp.htm |
| Funding | $30 million contract modification (September 2025) for CYFENDUS | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-contract-modification-valued, https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award, https://investors.emergentbiosolutions.com/node/23881/pdf, https://synapse.patsnap.com/article/emergent-biosolutions-secures-250m2B-in-contracts-for-key-medical-supplies-to-us-government, https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/pressrelease_010825.htm, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/exhibit108mod2-biothraxp.htm |
| Funding | $54 million contract award (March 2026) for CNJ-016 | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award |
| Funding | $235.8 million five-year contract (2024) for BioThrax | https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply |
| Production site | Winnipeg, Canada | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| Production site | Lansing, Michigan | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| Production site | Baltimore, Maryland (Bayview and Camden) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-nai-status-baltimore-bayview, https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Production site | Canton, Massachusetts | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Production site | Hattiesburg, Mississippi | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Production site | Rockville, Maryland | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Certification | No Action Indicated (NAI) status for Baltimore Bayview facility (March 2024) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-nai-status-baltimore-bayview |
| Certification | Voluntary Action Indicated (VAI) status for Camden facility (October 2023) | https://www.sec.gov/Archives/edgar/data/1367644/000136764423000169/ebs-20231005.htm |
| Regulatory approval | FDA approval for CYFENDUS (July 2023) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-us-fda-approval-drug-product, https://investors.emergentbiosolutions.com/node/23881/pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| Regulatory approval | FDA sBLA approval for raxibacumab manufacturing in Winnipeg (December 2025) | https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |

Independent sources: fiercepharma.com, sec.gov, synapse.patsnap.com

## Technologies

- [Defense bioeconomy](https://en.bioecon.ru/technology/defense-bioeconomy/)